Dr. Janet Hammond,
Chief Medical Officer
Dr. Janet Hammond, Chief Medical Officer, will support marketed and development compounds in the Valeant
portfolio such as
Diastat® AcuDialTM,
Zelapar®,
Tasmar®,
Cesamet®,
retigabine and taribavirin. Her
responsibilities include medical strategy, protocol development, post-marketing studies, communications and
safety. Dr. Hammond is trained in Internal Medicine, Infectious Diseases and Critical Care Medicine, and
comes to Valeant from Bristol-Myers Squibb where she was responsible for Anti-Infectives and HIV Global
Clinical Development. Earlier in her career, she was a Senior Clinical Research Physician and Clinical
Program Head in Clinical Development at GlaxoWellcome and subsequently head of Clinical Discovery for
Antivirals in the Center for Excellence in Clinical Drug Discovery (CEDD) at GlaxoSmithKline. Her
distinguished career includes an impressive list of accomplishments in clinical research, drug development,
discovery research and post marketing support during her ten years in the pharmaceutical industry. She
obtained her undergraduate medical training at the University of Cape Town, South Africa, and post-graduate
training in Internal Medicine and Critical Care Medicine. She was admitted as a Fellow of the College of
Physicians of South Africa and obtained her Ph.D. in epidemiology from the University of Cape Town. She
trained in Infectious Diseases at Duke University, N.C. and Johns Hopkins University, Baltimore, MD, where
she obtained a Masters in Clinical Investigation from the Johns Hopkins School of Hygiene and Public Health.
Dr. Susan Hall,
Vice President, Global Regulatory Sciences
Dr. Susan Hall heads Global Regulatory Sciences with responsibility for Regulatory Affairs and Compliance, Pharmacovigilance, Data Management and Medical Writing. She has extensive multi disciplinary and international
experience spanning 23 years in drug development and life cycle management across a broad range of
therapeutic areas, including Anti-Infectives, CNS, Dermatology, Cardiovascular, Respiratory and Metabolic,
as well as specialized expertise in Genomics. Dr. Hall initially worked at Beecham Pharmaceuticals within
the Pharmacokinetics Unit and then subsequently joined GlaxoSmithKline in the department of Clinical
Pharmacology, based in the United Kingdom. In 1992, Dr. Hall moved to the U.S and has held various management positions within
GlaxoSmithKline including Clinical Pharmacology, Project Management, and most recently, Regulatory Affairs.
Dr. Hall has managed global projects across the drug development continuum from Research to Commercial and
brings substantial project management, regulatory and drug discovery expertise as well as significant international regulatory dossier experience. Dr. Hall holds a B.S.
degree in Pharmacology from the University of Leeds, United Kingdom, and a Ph.D. in Pharmacokinetics from
the Department of Pharmacy, University of Manchester, United Kingdom.
Dr. Harry Mansbach,
Sr. Vice President, Drug Development
Dr. Harry Mansbach leads the company's clinical and pre-clinical
operations, pharmaceutical development and line extension development
for retigabine,
taribavirin,
Diastat AcuDial and
Cesamet. Before
joining Valeant, Dr. Mansbach was Chief Medical Officer and Vice
President, Clinical Development at Cortex Pharmaceuticals in Irvine,
Calif., an emerging biotech company specializing in central nervous
system (CNS) therapeutics. Prior to his position at Cortex, he
worked at GlaxoSmithKline in Research Triangle Park, N.C.
Dr. Mansbach has been involved with the development and -management
of a number of significant CNS products and is experienced in all
phases of drug development from pre-clinical testing through Phase 4.
Dr. Mansbach finished his neurology residency at the University of
Michigan Health System and completed subspecialty fellowship training
in cerebrovascular diseases at the Henry Ford Hospital in Detroit,
Michigan. He is Board certified in neurology and was a member of the
Department of Neurology senior staff in the Henry Ford Health System.
He earned his Bachelor's degree from Yale University and his M.D.
degree from the Duke University School of Medicine.
Rich Masterson,
Sr. Vice President, Global Commercial Development
Rich Masterson leads Valeant's Global Commercial Development function which encompasses Global Marketing,
Product Development, and Licensing & Business Development. He has more than eighteen years of experience in
the pharmaceutical industry spanning a broad range of commercial responsibilities in numerous therapeutic
areas. Prior to joining Valeant Mr. Masterson worked at TAP Pharmaceuticals Inc. where he was General
Manager of the Lupron franchise, a $900M business, and Vice President of Licensing. During his tenure in the
licensing department at TAP he completed fourteen transactions for products in development and on the
market. Prior to assuming responsibility for TAP's licensing function, Mr. Masterson held positions of
steadily increasing responsibility in the marketing and business development departments. He holds a BA
degree in economics from the University of Virginia and a Masters of Management degree from the Kellogg
Graduate School of Management, Northwestern University. Before joining industry, Mr. Masterson served seven
years in the Special Operations group of the U.S. Navy.
Julia Amo,
Vice President of Business Operations and Project Management
Ms. Amo is Vice President of Business Operations and Project Management. In this role, she is responsible
for developing and managing pre-clinical and clinical budgets across all therapeutic areas, budget
management and forecasting, and contract and scope of work negotiations. She is also responsible for
oversight of project timelines, issues/risks, and deliverables at the project and portfolio level.
Prior to joining Valeant, Ms. Amo ran a consulting business where she advised both Pharmaceutical and
Clinical Research Organizations on clinical research strategy, business planning, operations strategy,
project management structure, budget forecasting, and NDA acceleration strategies. Prior to consulting, Ms.
Amo held various management positions at Covance including Executive Director of Global Business Operations
where she directed pricing structure, contract and budget negotiations, and project management tracking and
oversight for over 145 Phase II/III clinical programs including five NDA's. During her tenure at Covance,
Ms. Amo was also Business Director of the company's Health Economics and Outcome Services Group. Previous to
Covance, Ms. Amo was the Director of Contract and Project Management for the Institute for Biological
Research and Development. Ms Amo began her career as an intensive care nurse specializing in acute trauma
and cardiac surgical intensive care.
Ms. Amo received a Bachelor of Science degree in Nursing from Niagara University and a Master in Business
Administration from Saint Joseph's University.
|
